Oncogenic regulation of tumor metabolic reprogramming

Míriam Tarrado-Castellarnau; Pedro de Atauri; Marta Cascante

doi:10.18632/oncotarget.10911

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Oncogenic regulation of tumor metabolic reprogramming

Míriam Tarrado-Castellarnau, Pedro de Atauri and Marta Cascante _

PDF | HTML | How to cite

Oncotarget. 2016; 7:62726-62753. https://doi.org/10.18632/oncotarget.10911

Metrics: PDF 3753 views | HTML 6230 views | ?

Abstract

Míriam Tarrado-Castellarnau1, Pedro de Atauri1 and Marta Cascante1

1 Department of Biochemistry and Molecular Biomedicine, Universitat de Barcelona, Institute of Biomedicine of Universitat de Barcelona (IBUB) and CSIC-Associated Unit, Barcelona, Spain

Correspondence to:

Marta Cascante, email:

Keywords: metabolic reprogramming, MYC, HIF, PI3K, mTOR

Received: February 03, 2016 Accepted: June 29, 2016 Published: July 28, 2016

Abstract

Development of malignancy is accompanied by a complete metabolic reprogramming closely related to the acquisition of most of cancer hallmarks. In fact, key oncogenic pathways converge to adapt the metabolism of carbohydrates, proteins, lipids and nucleic acids to the dynamic tumor microenvironment, conferring a selective advantage to cancer cells. Therefore, metabolic properties of tumor cells are significantly different from those of non-transformed cells. In addition, tumor metabolic reprogramming is linked to drug resistance in cancer treatment. Accordingly, metabolic adaptations are specific vulnerabilities that can be used in different therapeutic approaches for cancer therapy. In this review, we discuss the dysregulation of the main metabolic pathways that enable cell transformation and its association with oncogenic signaling pathways, focusing on the effects of c-MYC, hypoxia inducible factor 1 (HIF1), phosphoinositide-3-kinase (PI3K), and the mechanistic target of rapamycin (mTOR) on cancer cell metabolism. Elucidating these connections is of crucial importance to identify new targets and develop selective cancer treatments that improve response to therapy and overcome the emerging resistance to chemotherapeutics.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10911

Publication Alerts

Reviews:

Oncogenic regulation of tumor metabolic reprogramming

Abstract